91 related articles for article (PubMed ID: 9355963)
21. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit.
Grossberg SE; Kawade Y; Kohase M; Klein JP
J Interferon Cytokine Res; 2001 Sep; 21(9):743-55. PubMed ID: 11576468
[TBL] [Abstract][Full Text] [Related]
22. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
[TBL] [Abstract][Full Text] [Related]
23. beta-Endorphin augments the cytolytic activity and interferon production of natural killer cells.
Mandler RN; Biddison WE; Mandler R; Serrate SA
J Immunol; 1986 Feb; 136(3):934-9. PubMed ID: 2934481
[TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of monoclonal antibodies directed at epitopes of human IFN-gamma.
Wang CY; Bushkin Y; Chen PD; Platsoucas CD; Long C
Hybridoma; 1984; 3(4):321-32. PubMed ID: 6084639
[TBL] [Abstract][Full Text] [Related]
25. [Effect of interferon-alpha (MOR-22) on human NK cell activity].
Yanagihara Y; Tochizawa S; Ishii K; Hirai Y
Gan To Kagaku Ryoho; 1986 Feb; 13(2):342-8. PubMed ID: 3947110
[TBL] [Abstract][Full Text] [Related]
26. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
Nolte KU; Günther G; von Wussow P
Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
[TBL] [Abstract][Full Text] [Related]
27. Interferon--a major regulator of natural killer cell-mediated cytotoxicity.
Reiter Z
J Interferon Res; 1993 Aug; 13(4):247-57. PubMed ID: 7693829
[TBL] [Abstract][Full Text] [Related]
28. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
29. CD27 engagement by a soluble CD70 protein enhances non-cytolytic antiviral activity of CD56bright natural killer cells by IFN-γ secretion.
Jang YS; Kang W; Chang DY; Sung PS; Park BC; Yoo SH; Park YW; Shin EC
Clin Immunol; 2013 Dec; 149(3):379-87. PubMed ID: 24211844
[TBL] [Abstract][Full Text] [Related]
30. Analysis of antigenic domains on natural and recombinant human IFN-beta by the inhibition of biologic activities with monoclonal antibodies.
Redlich PN; Grossberg SE
J Immunol; 1989 Sep; 143(6):1887-93. PubMed ID: 2476486
[TBL] [Abstract][Full Text] [Related]
31. Different interactions of interferon-alpha subtypes at the surface of epithelial and lymphoid cells.
Overall ML; Chambers P; Hertzog PJ
J Interferon Res; 1992 Aug; 12(4):281-8. PubMed ID: 1431308
[TBL] [Abstract][Full Text] [Related]
32. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity.
Golub SH; D'Amore P; Rainey M
J Natl Cancer Inst; 1982 May; 68(5):711-7. PubMed ID: 6175788
[TBL] [Abstract][Full Text] [Related]
33. Biologic activities of natural and synthetic type I interferons.
Pfeffer LM
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-63-S9-69. PubMed ID: 9208874
[TBL] [Abstract][Full Text] [Related]
34. Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets.
Lebow LT; Jewett A; Bonavida B
J Immunol; 1993 Jan; 150(1):320-9. PubMed ID: 8417130
[TBL] [Abstract][Full Text] [Related]
35. Defective NK cell activity following thermal injury.
Klimpel GR; Herndon DN; Fons M; Albrecht T; Asuncion MT; Chin R; Stein MD
Clin Exp Immunol; 1986 Nov; 66(2):384-92. PubMed ID: 3493101
[TBL] [Abstract][Full Text] [Related]
36. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
Wright SC; Bonavida B
J Immunol; 1983 Jun; 130(6):2965-8. PubMed ID: 6189909
[TBL] [Abstract][Full Text] [Related]
37. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
38. Biological characterization of three novel variants of IFN-alpha 13 produced by human placental trophoblast.
Fink T; Zachar V; Ebbesen P
Placenta; 2001; 22(8-9):673-80. PubMed ID: 11597187
[TBL] [Abstract][Full Text] [Related]
39. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function.
Jiang W; Zhang C; Tian Z; Zhang J
Gene Ther; 2013 Nov; 20(11):1062-9. PubMed ID: 23759701
[TBL] [Abstract][Full Text] [Related]
40. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
